Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis.

Ecancermedicalscience · 2020 · PMC7373642 · PMID 32728385

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

marginally significantp = 0.053so close (0.05 < p ≤ 0.1)

Rechallenge at the fourth line or later lines was marginally significant (HR: 1.18, 95% CI 0.99–3.32, p = 0.053).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.